KIND Presents Positive Results of AND017 to Treat Anemia Associated with Chronic Kidney Disease in Two Phase II and Two Phase I

The four clinical trials are first-in-human trial in healthy subjects.

KIND Announces FDA Granted Orphan Drug Designation (ODD) for AND017 in the Treatment of Sickle Cell Disease (SCD)

Sickle Cell Disease (SCD) affects around 120,000 patients in US and more than 8,000,000 worldwide.

KIND Announces Late-Breaking Abstract Accepted for Presentation on AND017 Clinical Trials to Treat Anemia in Chronic Kidney Disease (CKD) at ASN - Kidney Week 2024

The abstract on the AND017 Phase 2 clinical trial for treatment of anemia in dialysis-dependent chro

Kind Pharmaceuticals Announces Settlement

KIND announced a resolution of the recent dispute with FibroGen, Inc. regarding HIF- PHI technology.

The Third Generation Oral Breast Cancer Drug AND019 Received FDA IND Approval

On October 1st, the third-generation oral breast cancer new drug, AND019, independently developed by

Congratulations! AND017 Received U.S. FDA Official IND Approval and Enters Phase 2 Clinical Trials

On January 14, 2021, Kind Pharmaceuticals LLC received the formal notification from the US FDA appro

Joyous News! Kind Pharmaceuticals Holds a Groundbreaking Ceremony for the Production Base at Yuhang District of Hangzhou

In the morning of Oct. 17, 2020, Kind Pharmaceuticals LLC held a groundbreaking ceremony at a new R&

Congrats to CRISPR gene editing system being awarded the Nobel Prize in Chemistry 2020

In the afternoon of October 7th 2020, the Royal Swedish Academy of Sciences awarded the Nobel Prize

Reveal of the Nobel Prize in Physiology or Medicine 2019

On October 7th, 2019, the Nobel Assembly at Karolinska Institutet announced the awarding of the 2019

Initiation of Phase 1 Clinical Trial of New Anemia Drug AND017 in Australia by Kind Pharmaceuticals LLC

Kind Pharmaceuticals LLC announced that their new drug AND017 for anemia developed by using their pr